NAGE:NASDAQNiagen Bioscience, Inc. analysis
Data as of Sep 8, 2026 - not real-time
- Latest price
- $3.17
- Risk: high
- 9/10High risk
Summary
Niagen Bioscience, Inc. trades at $3.17, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. It has lost 1.2% over the past 30 days. With RSI at 48.4 the momentum picture is neutral, alongside a bullish MACD signal. The recent range runs from support at $2.96 up to resistance at $3.34.
Valuation screens as fair, on a P/E of 16.7 with no clean sector comparison available. Sell-side targets cluster 281.2% above the current quote. Revenue is contracting at 4.3% on a 12.4% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 57.7%, a beta of 1.25 and a maximum drawdown of 71.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.
Valuation screens as fair, on a P/E of 16.7 with no clean sector comparison available. Sell-side targets cluster 281.2% above the current quote. Revenue is contracting at 4.3% on a 12.4% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 57.7%, a beta of 1.25 and a maximum drawdown of 71.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.
Top market events
- LOS ANGELES AP — LOS ANGELES AP — Niagen Bioscience, Inc.
- Niagen Bioscience NAGE is scheduled to announce Q2 earnings results on Tuesday.
- Niagen Bioscience Inc NAGE reports strong TrueNiagen sales growth, China cross-border revenue exceeding full-year 2025...
Market outlook
Short term
< 1 yearNeutral
Model confidence1/101 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 4.66
- MACD momentum is positive
Medium term
1–3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 4.66
- Analyst targets imply +281.2% versus the current price
Long term
> 3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Analyst targets imply +281.2% versus the current price
- Revenue contracting at -4.3%
- P/E ratio of 16.7
Key metrics
Financial health
Revenue Growth-4.30%
Profit Margin12.39%
P/E Ratio16.7
ROE21.80%
ROA5.44%
Debt/Equity2.82
P/B Ratio3.0
Op. Cash Flow$5.9M
Free Cash Flow$1.6M
Technical analysis
TrendBearish
RSI48.4
Support$2.96
Resistance$3.34
MA 20$3.14
MA 50$3.26
MA 200$4.66
MACDBullish
VolumeDecreasing
Fear & Greed Index93.23
Valuation
Fair Value$1.07
Target Price$12.08
Upside/Downside281.18%
GradeFair
TypeBlend
Risk assessment
Beta1.25
Volatility57.74%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.